Compare NSSC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | WVE |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | Singapore |
| Employees | 1061 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 1994 | 2015 |
| Metric | NSSC | WVE |
|---|---|---|
| Price | $37.95 | $6.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $48.17 | $29.81 |
| AVG Volume (30 Days) | 464.1K | ★ 3.3M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $181,621,000.00 | $3,704,000.00 |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | $85.67 |
| P/E Ratio | $54.86 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $29.27 | $5.02 |
| 52 Week High | $47.61 | $21.73 |
| Indicator | NSSC | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 52.15 |
| Support Level | $37.43 | $6.02 |
| Resistance Level | $38.25 | $6.31 |
| Average True Range (ATR) | 1.16 | 0.30 |
| MACD | 0.23 | 0.10 |
| Stochastic Oscillator | 56.41 | 72.43 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.